Benzinga | Dec 3, 2021 05:21AM EST

Baird Initiates Coverage On Vor Biopharma with Outperform Rating, Announces Price Target of $38

Baird analyst Jack Allen initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Outperform rating and announces Price Target of $38.